# Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer

> **NCT00085813** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 70 (—)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** Ispinesib

## Key facts

- **NCT ID:** NCT00085813
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 70 (—)
- **Last updated:** 2010-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00085813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00085813, "Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00085813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*